Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026

▤ Summary

Personalis presented new clinical data for its NeXT Personal MRD test at ASCO 2026. The company said the test detected colorectal cancer recurrence early and showed ultrasensitive performance across six solid tumor types. The release also highlighted strong results in lung, ovarian, endometrial, melanoma, and renal cell carcinoma studies. These findings support Personalis’ positioning of NeXT Personal as a tool for earlier relapse detection and treatment guidance.

▦ Linked Companies